Pharmacogenomics in the treatment of parkinson???s disease.

Chandrima Saha.

Parkinson's sickness (PD) is the second most normal neurodegenerative problem with expanding proof of hereditary factor adding to its etiology. Accessibility of successful pharmacological treatment recognizes it from other neurodegenerative issues. The nigrostriatal dopaminergic pathway is the objective for the majority of the accessible treatments.For suggestive alleviation L-dopa in mix with carbidopa is the medication of decision separated from which dopamine agonists (DAs), catecol-O-methyltransferase (COMT) inhibitors and monoamine oxidase inhibitors are different medications.